Table 3.
Impact of CAV1 genotype on graft histological lesions
| Biopsies | CAV1 genotype | ||
|---|---|---|---|
| AA | AC | CC | |
| Systematic | n = 10 | n = 43 | n = 69 |
| Acute tubular necrosis | 0 | 0 | 1 (1.4%) |
| Tacrolimus acute tubular toxicity | 1 (10.0%) | 7 (16.3%) | 18 (26.1%) |
| Tacrolimus chronic vascular toxicity | 1 (10.0%) | 5 (11.6%) | 7 (10.1%) |
| Acute rejection (cellular or humoral) | 0 | 1 (2.3%) | 7 (10.1%) |
| IF/TA grade I or II | 5 (50.0%) | 14 (32.6%) | 18 (26.1%) |
| IF/TA grade III | 0 | 1 (2.3%) | 1 (1.4%) |
| Clinically indicated biopsies | n = 7 | n = 38 | n = 49 |
| Acute tubular necrosis | 2 (28.6%) | 12 (31.6%) | 11 (22.4%) |
| Tacrolimus acute tubular toxicity | 1 (14.3%) | 5 (13.2%) | 9 (18.4%) |
| Tacrolimus chronic vascular toxicity | 2 (28.6%) | 7 (18.4%) | 9 (18.4%) |
| Acute rejection (cellular or humoral) | 1 (14.3%) | 9 (23.7%) | 11 (22.4%) |
| IF/TA grade I or II | 5 (71.4%)* | 11 (28.9%)* | 5 (10.2%)* |
| IF/TA grade III | 0 | 1 (2.6%) | 3 (6.1%) |
| Total of biopsies | n = 17 | n = 81 | n = 118 |
| Acute tubular necrosis | 2 (11.8%) | 12 (14.8%) | 12 (10.2%) |
| Tacrolimus acute tubular toxicity | 3 (17.6%) | 12 (14.8%) | 27 (22.9%) |
| Tacrolimus chronic vascular toxicity | 3 (17.6%) | 12 (14.8%) | 16 (13.5%) |
| Acute rejection (cellular or humoral) | 1 (5.9%) | 10 (12.3%) | 11 (9.3%) |
| IF/TA grade I or II | 10 (58.8%)** | 25 (30.8%)** | 23 (19.5%)** |
| IF/TA grade III | 0 | 3 (3.7%) | 3 (2.5%) |
| BK virus nephropathy | 2 (11.8%) | 3 (3.7%) | 4 (3.4%) |
* P < 0.05. ** P < 0.01.